We have recently shown that successful ICI therapy induces an expansion of the peripheral CX3CR1+ CD8+ T-cell subset that includes an enriched repertoire of tumor-specific and tumor-infiltrating CD8+ T cells in preclinical models (16). The gene discussed is CD8A; the disease is neoplasm.